Frenchtown, NJ, United States of America

Robert F Graziano

USPTO Granted Patents = 23 (Patent Applications = 11)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 4.4

ph-index = 14

Forward Citations = 977(Granted Patents)

Location History:

Princeton, NJ (US) (2008 - 2012)
Frenchtown, NJ (US) (1998 - 2022)

Company Filing History:

University of Massachusetts

patents

3 out of 3,681

Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

patents

8. 1 out of 45

Celldex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 1998-2022

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11242393 - Antibodies against MICA and/or MICB and uses thereof (2022-02-08),

2. 10688180 - Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer (2020-06-23),

3. 9789182 - Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer (2017-10-17),

4. 9217029 - Antibodies against clostridium difficile toxins and uses thereof (2015-12-22),

5. 8609111 - Antibodies against clostridium difficile toxins and uses thereof (2013-12-17),

6. 8257709 - [object Object] (2012-09-04),

7. 8236311 - Antibodies against clostridium difficile toxins and uses thereof (2012-08-07),

8. 8142778 - Methods of treatment using CTLA-4 antibodies (2012-03-27),

9. 8088377 - Human monoclonal antibodies against CD30 (2012-01-03),

10. 7625559 - [object Object] (2009-12-01),

11. 7452535 - Methods of treatment using CTLA-4 antibodies (2008-11-18),

12. 7387776 - Human monoclonal antibodies against CD30 (2008-06-17),

13. 7378504 - Human monoclonal antibodies to Fc gamma receptor I (CD64) (2008-05-27),

14. 7316812 - Cells expressing anti-Fc receptor binding components (2008-01-08),

15. 6682928 - Cells expressing anti-Fc receptor binding components (2004-01-27),

Title: The Innovative Contributions of Robert F Graziano in Cancer Treatments

Introduction: Robert F Graziano, based in Frenchtown, NJ, has made significant advancements in the field of biotechnology through his innovative inventions. With a portfolio that boasts 23 patents, Graziano has played a crucial role in developing therapies for cancer treatment, particularly through his research into antibodies.

Latest Patents: Among Graziano’s notable patents are “Antibodies against MICA and/or MICB and uses thereof” and “Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer.” The first patent focuses on antibodies that specifically bind to human MICA/B, exploring their potential in treating cancer by administering anti-MICA/B antibodies. The second patent discusses a method for treating various cancer types, where anti-KIR antibodies are used in combination with anti-CTLA-4 antibodies to enhance treatment effectiveness.

Career Highlights: Throughout his career, Graziano has been associated with reputable organizations, including Medarex Inc. and the University of Massachusetts. His work in these institutions has facilitated groundbreaking research and patent filings that contribute to the advancement of cancer therapies.

Collaborations: Graziano’s collaborations with other distinguished professionals, such as Yashwant M Deo and Tibor P Keler, have further propelled his research efforts. These partnerships have enabled the sharing of knowledge and resources, ultimately leading to the successful development of innovative cancer treatment approaches.

Conclusion: Robert F Graziano’s contributions to the field of cancer therapeutics exemplify the power of innovation in science. His patents reflect a deep commitment to improving patient outcomes, showcasing the importance of research and collaboration in tackling complex health challenges.

This text is generated by artificial intelligence and may not be accurate.